HK Stock Market Move | DUALITYBIO-B(09606) rose 5% in early trading, the company plans to go public on the Sci-Tech Innovation Board, with its Hong Kong stocks rising nearly 5 times in the past six months.

DUALITYBIO-B (09606) rose 5% in the morning session, as of the reporting deadline, it rose by 3.41% to 345.6 Hong Kong dollars, with a turnover of 5.99 billion Hong Kong dollars. On the news front, Ying En Biotechnology announced that the company's board of directors has decided to list on the Sci-Tech Innovation Board, subject to market conditions, and further approval by the board of directors, approval by the shareholders' meeting, and regulatory approval. It is reported that on April 15th of this year, Ying En Biotechnology officially listed on the main board of the Hong Kong Stock Exchange, with an IPO fundraising total exceeding 1.5 billion Hong Kong dollars, making it one of the largest IPOs in the Hong Kong stock market's 18A sector in nearly four years. The listing price on the Hong Kong stock market was 94.6 Hong Kong dollars per share, and the stock price reached a high of 563.5 Hong Kong dollars in September, with a maximum increase of 495.67%. According to a report from Zhongjin Research, based on Frost & Sullivan, the global ADC market is expected to reach approximately 10.4 billion U.S. dollars by 2023, and is estimated to reach 115.1 billion U.S. dollars by 2032. According to the announcement of Ying En Biotechnology, the company plans to submit an application for the commercialization of DB-1303 (HER2 ADC) for endometrial cancer in the United States and for breast cancer in China by 2025. The company's DB-1311 (B7-H3 ADC) has shown the best potential in prostate cancer, DB-1310 (HER3 ADC) is expected to catch up later; DB-1305 (TROP2 ADC) and the combination of dual antibodies are exploring leading global progress, while self-immersion and dual antibody ADCs continue to drive the exploration of the next generation of ADC frontier.